Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion, a clinical-stage biotech company focused on diabetes and obesity treatments, has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for the underwriter to purchase additional shares and is subject to market conditions, with no assurance it will be completed as …